Vitamin E shows promise for NASH patients

11/11/2009 | MedPage Today (free registration)

Researchers said 43% of nonalcoholic steatohepatitis patients taking vitamin E for two years met a clinical trial primary endpoint of improved liver function, decreased ballooning and stabilization of fibrosis, compared with less than 20% of patients on a placebo. NASH patients taking pioglitazone or Actos also improved but did not meet the trial's primary endpoint.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC